


Serial No. 10/623,972

Filed: July 21, 2003

IN THE CLAIMS

1. (Currently amended) A compound of formula:



I,

wherein

R¹ is selected from the group

- H,
- COR⁴, and
- COOCHR⁵OCOR⁴;

R² and R³ are independently selected from

- H, and
- OR⁵;

R⁴ is selected from the group

- C₁₋₆ alkyl,
- lower alkyl substituted by up to 4 groups independently selected from
- NR⁵R⁶,
- SR⁵,
- OR⁵,

Serial No. 10/623,972

Filed: July 21, 2003

-aryl,
-aryl substituted by up to 2 groups independently selected from
-OR⁵ and C₁₋₄ lower alkyl, and
-heteroaryl, and
-heterocycle;

R⁵ and R⁶ are independently selected from

-H, and
- C₁₋₆ lower alkyl,

or, alternatively, -NR⁵R⁶ can form a ring having 3 to 7 atoms, said ring optionally including one or more additional N or O atoms;

or the pharmaceutically acceptable salts thereof.

2. (Original) The compound of claim 1 wherein R¹ is -COR⁴.

3. (Original) The compound of claim 2 wherein R² is H.

4. (Original) The compound of claim 3 wherein R³ is H.

5. (Previously presented) The compound of claim 4 which is selected from the group:

N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylacetamide;

N-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylpropanamide;

Serial No. 10/623,972

Filed: July 21, 2003

2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylacetamide acetic acid salt;

2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylacetamide hydrochloric acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide;

(2*S*)-2-amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide acetic acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide hydrochloric acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-3-phenyl-*N*-phenylpropanamide;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-3-phenyl-*N*-phenylpropanamide hydrochloric acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methyl-*N*-phenylpentanamide acetic acid salt;

(2*S*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methyl-*N*-phenylpentanamide hydrochloric acid salt;

(2*S*)-2-Amino-3-(4-hydroxyphenyl)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylpropanamide hydrochloric acid salt;

Serial No. 10/623,972

Filed: July 21, 2003

(2S)-2,6-Diamino-N-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylhexanamide di-hydrochloric acid salt;

(2S)-2-Amino-3-indol-3-yl-N-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylpropanamide hydrochloric acid salt ;

(2S)-2-Amino-3-hydroxy-N-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylpropanamide;

(2R)-2-Amino-N-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-N-phenylbutanamide hydrochloric acid salt;

N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylpentanamide; and

N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylbutanamide.

6. (Previously presented) The compound of claim 2 which is selected from the group:

N-(4-Hydroxyphenyl)-N-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]acetamide; and

N-(4-methoxyphenyl)-N-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]acetamide.

7. (Original) The compound of claim 1 wherein R¹ is -COOCHR⁵OCOR⁴.

8. (Original) The compound of claim 7 wherein R² is H.

Serial No. 10/623,972

Filed: July 21, 2003

9. (Original) The compound of claim 8 wherein R^3 is H.

10. (Previously presented) The compound of claim 9 which is selected from the group:

{*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylcarbamoyloxy}methyl acetate;

{*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylcarbamoyloxy}methyl 2-(dimethylamino)acetate;

{*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylcarbamoyloxy}methyl 2-(dimethylamino)acetate hydrochloric acid salt; and

{*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylcarbamoyloxy}methyl piperidine-4-carboxylate trifluoroacetic acid salt.

11. (Original) The compound of claim 1 wherein R^1 is H.

12. (Original) The compound of claim 11 wherein R^2 is H.

13. (Previously presented) The compound of claim 12 which is selected from the group:

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one;

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one methanesulfonate salt;

Serial No. 10/623,972

Filed: July 21, 2003

7-[(4-Hydroxyphenyl)amino]-3-(4-methoxyphenyl)-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one; and

3-(4-Methoxyphenyl)-7-[(4-methoxyphenyl)amino]-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one.

14. (Original) A compound selected from the group:

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one,

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one methanesulfonate salt,

7-[(4-Hydroxyphenyl)amino]-3-(4-methoxyphenyl)-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one, and

3-(4-Methoxyphenyl)-7-[(4-methoxyphenyl)amino]-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one.

15. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and pharmaceutically acceptable carrier or excipient.

Claim 16. (Canceled).

Claim 17. (Canceled).

Serial No. 10/623,972

Filed: July 21, 2003

18. (Previously presented) A method of- treating lung, colon or prostate cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1.

Claim 19. (Cancelled).

20. (Previously presented) A compound selected from the group:

(Chloromethoxy)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-benzamide,

3-(4-Methoxyphenyl)-1-phenyl-7-[[4-(1,1,2,2-tetramethyl-1-silapropoxy) phenyl]amino]-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one, and

N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-[4-(1,1,2,2-tetramethyl-1-silapropoxy)phenyl]acetamide.


Serial No. 10/623,972
Filed: July 21, 2003

REMARKS

With entry of the present amendment claims 1-15, 18 and 20 are pending and are allowed. Claim 1 is amended to include a reference to pharmaceutically acceptable salts. This amendment is supported by the specification, for example at [0010]. Claim 19 is cancelled.

Applicants believe that no fee is due with this communication. However, should the Patent Office determine that a fee is owed, or a credit is due to applicant, the Patent Office is hereby authorized to charge any required fees, including any extension of time and/or excess claim fees, or credit any overpayment, to applicant's Deposit Account 08-2525 as appropriate.

Respectfully submitted,



Attorney for Applicant(s)
Patricia S. Rocha-Tramaloní
(Reg. No. 31,054)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-2441
Telefax: (973) 235-2363

158096